CoChat

Evidence for altered insulin receptor signaling in Alzheimer's disease

Griffith, Chelsea M., Eid, Tore, Rose, Gregory M., Patrylo, Peter R. · 2018 · Neuropharmacology
Cited by 61

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Epidemiological data have shown that metabolic disease can increase the propensity for developing cognitive decline and dementia, particularly Alzheimer's disease (AD). While this interaction is not completely understood, clinical studies suggest that both hyper‐ and hypoinsulinemia are associated with an increased risk for developing AD. Indeed, insulin signaling is altered in post‐mortem brain tissue from AD patients and treatments known to enhance insulin signaling can improve cognitive function. Further, clinical evidence has shown that AD patients and mouse models of AD often display alterations in peripheral metabolism. Since insulin is primarily derived from the periphery, it is likely that changes in peripheral insulin levels lead to alterations in central nervous system (CNS) insulin signaling and could contribute to cognitive decline and pathogenesis. Developing a better understanding of the relationship between alterations in peripheral metabolism and cognitive function might provide a foundation for the development of better treatment options for patients with AD. In this article we will begin to piece together the present data defining this relationship by briefly discussing insulin signaling in the periphery and CNS, its role in cognitive function, insulin's relationship to AD, peripheral metabolic alterations in mouse models of AD and how information from these models helps understand the mechanisms through which these changes potentially lead to impairments in insulin signaling in the CNS, and potential ways to target insulin signaling that could improve cognitive function in AD. This article is part of the Special Issue entitled ‘Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.’ HighlightsMetabolic disease increases the risk of developing cognitive decline and dementia.AD is associated with peripheral metabolic alterations.Insulin/insulin sensitivity is altered in the AD brain.Insulin and Insulin sensitizers can improve cognitive function in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2018.01.008

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 61

Metadata

Authors
Griffith, C. M., Eid, T., Rose, G. M., & Patrylo, P. R.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2018-07
Volume
136
Issue
Pt B
Pages
202-215
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2784120689
Cited by
61
References
66
FWCI
4.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evidence for altered insulin receptor signaling in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.01.008
The paper
Griffith, C. M., Eid, T., Rose, G. M., & Patrylo, P. R. (2018). Evidence for altered insulin receptor signaling in Alzheimer's disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.01.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.